Table 1.
Patients’ characteristics at the time of entering the study and surgical data.
| Phase A | Phase B1 | Phase B2 | |||||
|---|---|---|---|---|---|---|---|
| Control CABG | Control Mechanical Prostheses | Biological Prostheses | Control CABG | Control Mechanical Prostheses | Biological Prostheses | ||
| PATIENTS (number) | 112 | 49 | 37 | 301 | 45 | 36 | 477 |
| Male—total no. (%) | 59 (52.3) | 37 (75.5) | 27 (77.1) | 175 (58.5) | 41 (91.1) | 25 (71.4) | 328 (68.8) |
| Age—yr, mean (SD) | 76.9 (11.0) | 69.4 (7.6) | 59.6 (12.1) | 74.8 (7.8) | 76.2 (5.8) | 70.7 (9.5) | 79.1 (7.4) |
| Diabetes mellitus—total no. (%) | 30 (26.8) | 19 (30.6) | 6 (17.1) | 89 (29.8) | 10 (22.2) | 12 (34.3) | 132 (27.9) |
| Hypertension—total no. (%) | 90 (80.4) | 41 (85.4) | 24 (68.6) | 251 (84.2) | 35 (79.6) | 23 (65.7) | 400 (84.9) |
| MI—total no. (%) | NR | 49 (100) | 1 (2.7) | 16 (5.4) | 45 (100) | 0 (0) | 36 (7.6) |
| NO donors—total no. (%) | 5 (4.5) | 4 (8.2) | 0 (0) | 11 (3.7) | NR | NR | 18 (3.8) |
| Statins—total no. (%) | 64 (57.1) | 33 (67.3) | 15 (40.5) | 174 (57.8) | NR | NR | 284 (59.5) |
| OAC—total no. (%) | 30 (26.8) | 5 (10.2) | 6 (16.2) | 43 (14.3) | NR | NR | 105 (22.0) |
| APT—total no. (%) | 48 (42.9) | 35 (71.4) | 7 (18.9) | 111 (36.9) | NR | NR | 238 (49.9) |
| SURGICAL DATA | |||||||
| Valve Surgery + CABG—total no. (%) | 14 (12.5) | NR | NR | NR | NR | NR | NR |
| Cross-clamp time—min | |||||||
| Median | NR | 36.6 | 48.6 | 43.2 | NR | NR | NR |
| IQR | 33.0–44.4 | 38.4–57.6 | 33.0–57.0 | ||||
| CPB time—min | |||||||
| Median | NR | 69.0 | 63.9 | 58.8 | NR | NR | NR |
| IQR | 60.6–75.6 | 52.2–72.6 | 44.4–72.0 | ||||
APT, antiplatelet drugs; CPB, cardiopulmonary bypass; IQR, interquartile range; MI, myocardial infarction; NO, nitric oxide; NR, not recorded; OAC, oral anticoagulant drugs.